These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29163965)

  • 1. Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
    Pinter M; Weinmann A; Wörns MA; Hucke F; Bota S; Marquardt JU; Duda DG; Jain RK; Galle PR; Trauner M; Peck-Radosavljevic M; Sieghart W
    United European Gastroenterol J; 2017 Nov; 5(7):987-996. PubMed ID: 29163965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors.
    Nuzzo PV; Adib E; Weise N; Curran C; Stewart T; Freeman D; Nassar AH; Abou Alaiwi S; Bakouny Z; McGregor BA; Choueiri TK; Jain RK; McKay RR; Sonpavde G
    Clin Genitourin Cancer; 2022 Aug; 20(4):301-306. PubMed ID: 35614012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
    Kim KM; Roh JH; Lee S; Yoon JH
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101510. PubMed ID: 33272886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy.
    Feng LH; Sun HC; Zhu XD; Zhang SZ; Li KS; Li XL; Li Y; Tang ZY
    Ann Transl Med; 2019 Dec; 7(23):739. PubMed ID: 32042755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Tozuka T; Yanagitani N; Yoshida H; Manabe R; Ogusu S; Tsugitomi R; Sakamoto H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Seike M; Gemma A; Nishio M
    Anticancer Res; 2021 Apr; 41(4):2093-2100. PubMed ID: 33813419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.
    Bang CN; Greve AM; Køber L; Rossebø AB; Ray S; Boman K; Nienaber CA; Devereux RB; Wachtell K
    Int J Cardiol; 2014 Aug; 175(3):492-8. PubMed ID: 25012498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation.
    Fischer-Rasokat U; Bänsch C; Renker M; Rolf A; Charitos EI; Weferling M; Liebetrau C; Herrmann E; Choi YH; Hamm CW; Kim WK
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):815-824. PubMed ID: 35441662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study.
    Landolfo M; Maino A; Di Salvo E; Fiorini G; Peterlana D; Borghi C
    Intern Emerg Med; 2022 Aug; 17(5):1335-1341. PubMed ID: 35064437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry.
    Park CS; Yang HM; Kang J; Han JK; Park KW; Kang HJ; Koo BK; Seung KB; Cha KS; Seong IW; Rha SW; Jeong MH; Kim HS
    Front Cardiovasc Med; 2022; 9():994419. PubMed ID: 36119742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Renin-Angiotensin System Inhibitors on bone fracture risk: a nationwide nested case-control study.
    Kim KM; Hwang EJ; Lee S; Yoon JH
    BMC Musculoskelet Disord; 2024 Jan; 25(1):3. PubMed ID: 38166774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
    Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
    J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy.
    Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
    Open Heart; 2022 Dec; 9(2):. PubMed ID: 36600585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy.
    Nardin M; Verdoia M; Gioscia R; Negro F; De Luca G
    Nutr Metab Cardiovasc Dis; 2021 Apr; 31(4):1276-1285. PubMed ID: 33549433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of early initiation of renin-angiotensin blockade on renal function and clinical outcomes in patients with hypertensive emergency: a retrospective cohort study.
    Endo K; Hayashi K; Hara Y; Miyake A; Takano K; Horikawa T; Yoshino K; Sakai M; Kitamura K; Ito S; Imai N; Fujitani S; Suzuki T
    BMC Nephrol; 2023 Mar; 24(1):68. PubMed ID: 36949416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D levels condition the outcome benefits of renin-angiotensin system inhibitors (RASI) among patients undergoing percutaneous coronary intervention.
    Verdoia M; Nardin M; Rolla R; Negro F; Gioscia R; Saghir Afifeh AM; Viglione F; Suryapranata H; Marcolongo M; De Luca G;
    Pharmacol Res; 2020 Oct; 160():105158. PubMed ID: 32841717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
    Blute ML; Rushmer TJ; Shi F; Fuller BJ; Abel EJ; Jarrard DF; Downs TM
    J Urol; 2015 Nov; 194(5):1214-9. PubMed ID: 26173101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of COVID-19 Hospitalized Patients Previously Treated with Renin-Angiotensin System Inhibitors.
    Cordeanu EM; Jambert L; Severac F; Lambach H; Tousch J; Heitz M; Mirea C; Hamadé A; Younes W; Frantz AS; Merdji H; Schini-Kerth V; Bilbault P; Meziani F; Ohlmann P; Andres E; Stephan D
    J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33126565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between early worsening of kidney function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis.
    Yuan S; Liu Y; He W; Jin J; Liu L; He Q
    Nephrology (Carlton); 2021 Oct; 26(10):772-781. PubMed ID: 34165226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.